Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer.
about
Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain.Bone-Targeted Imaging and Radionuclide Therapy in Prostate CancerEnzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.
P2860
Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Evolution of the treatment par ...... ion-resistant prostate cancer.
@en
type
label
Evolution of the treatment par ...... ion-resistant prostate cancer.
@en
prefLabel
Evolution of the treatment par ...... ion-resistant prostate cancer.
@en
P2093
P2860
P1433
P1476
Evolution of the treatment par ...... tion-resistant prostate cancer
@en
P2093
Alison Birtle
Chinnamani Vee Eswar
Heather Payne
Mohammad Butt
Simon Chowdhury
Simon Hughes
Zafar Malik
P2860
P2888
P304
P356
10.1007/S12325-013-0070-Z
P407
P577
2013-11-26T00:00:00Z
P6179
1012009321